Jasper Therapeutics, Inc.

Contributing Author

Recent Articles by Jasper Therapeutics, Inc.

Jun-14	Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria JSPR GlobeNewswire
Jun-03	Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress JSPR GlobeNewswire
May-14	Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
May-12	Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire